Skip to main content
. 2019 Jan 16;14(1):e0209605. doi: 10.1371/journal.pone.0209605

Fig 3. Predicted resistance to antiretroviral drugs in the German HIV-1 Seroconverter Study Cohort (1996–2017).

Fig 3

*: first line-regimen; **: no longer recommended in European ART guidelines; /r: ritonavir-boosted; 3TC: lamivudine; ABC: abacavir; AZT: zidovudine; D4T: stavudine; DDI: didanosine; FTC: emtricitabine; TDF: tenofovir disoproxil fumarate; EFV: efavirenz; ETR: etravirine; NVP: nevirapine; RPV: rilpivirine; ATV: atazanavir; DRV: darunavir; FPV: fosamprenavir; IDV: indinavir; LPV: lopinavir; NFV: nelfinavir; SQV: saquinavir; TPV: tipranavir.